Heart Failure Clinical Trial
Safety Study of Pyridostigmine in Heart Failure
Summary
Heart failure, a common heart disease affecting nearly 6 million Americans, is associated with high rates of hospitalization and death. Abnormalities in the autonomic nervous system are thought to play an important role in the progression of heart failure. This proposal aims to determine whether novel application of pyridostigmine, a drug currently approved by the FDA only for the treatment of neuromuscular disease, can improve autonomic nervous system function in heart failure patients.
Full Description
Autonomic dysregulation of the cardiovascular system, characterized by heightened sympathetic activity and withdrawal of parasympathetic activity promotes progression of heart failure. Pharmacological blockade of sympathetic overactivity is associated with reduced mortality risk, but there are few data on pharmacologic augmentation of parasympathetic withdrawal. Acetylcholinesterase inhibitors augment parasympathetic neurotransmission by blocking the enzymatic breakdown of acetylcholine at cholinergic receptor sites. Pyridostigmine is a short-acting, reversible acetylcholinesterase inhibitor approved by the FDA for the treatment of myasthenia gravis. Investigators propose a Phase II prospective randomized, double-blind trial to compare 12 weeks of treatment with ascending doses of pyridostigmine (15, 30, and 60 mg every 8 hours) vs. matching placebo in 60 patients with symptomatic chronic heart failure associated with left ventricular systolic dysfunction.
Eligibility Criteria
Inclusion Criteria:
Age 21-75 years
Symptomatic NYHA Class II-III heart failure >6 months
Left ventricular ejection fraction <35%
Previous implantation of implantable cardiovertor defibrillator or pacemaker
Guideline-recommended heart failure treatment for > 3 months
Able and willing to provide written informed consent
Exclusion Criteria:
Contraindications to cholinergic stimulation
Heart failure primarily attributable to genetic, valvular, infiltrative diseases
Persistent atrial fibrillation
Sick sinus syndrome
Pacemaker dependency during exercise
Severe chronotropic incompetence with peak exercise heart rate < 100 min-1
Severe exercise intolerance (unable to complete first stage of Bruce Protocol)
Coronary or cerebral atherothrombotic events within the past year
Hospitalization of emergency room visit for heart failure within last 3 months
ICD shock in last 6 months
Diabetes mellitus with peripheral neuropathy
Autonomic or peripheral neuropathy of any cause
Systolic blood pressure <90 or >160 mmHg
Resting heart rate <60 or >100 min-1
Serum sodium < 132 mmol/L
Serum creatinine >2.5 mg/dl
Liver function tests >3 times upper limit of normal
Severe anemia (Hemoglobin <10 gm/dl)
FEV1.0 < 60% of predicted or FEV1.0/FVC ratio <70%
PR interval >240 msec or second or third degree heart block on electrocardiogram
Exercise limited primarily by angina or non-cardiac co-morbid condition
Pregnant or breast-feeding women
Current treatment with medications known to interact with pyridostigmine
Known intolerance of oral preparations containing bromides
Any condition (e.g., psychiatric illness or active substance abuse) or situation that, in the investigator's opinion, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's ability to adhere with study procedures.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.